What is Cellectar Biosciences?
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel drugs for cancer treatment. The company's lead candidate, CLR 131 (iopofosine I-131), is a phospholipid drug conjugate (PDC) currently undergoing Phase 2 clinical studies for various B-cell malignancies, including relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma. Additionally, CLR 131 is being evaluated in Phase 1 studies for pediatric patients with select solid tumors and lymphomas, as well as for relapsed or refractory head and neck cancer. The company's focus on targeted therapies aims to provide more effective and less toxic treatment options for patients battling challenging forms of cancer.
How much funding has Cellectar Biosciences raised?
Cellectar Biosciences has raised a total of $199.6M across 14 funding rounds:
Stock Offering
$9.2M
Stock Offering
$7.8M
Stock Offering
$16.6M
Stock Offering
$10M
Debt
$150K
Share Placement
$102.9M
Stock/Share Issuance
$2.5M
Stock Issuance/Offering (2016): $9.2M supported by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2017): $7.8M featuring Undisclosed
Stock Issuance/Offering (2018): $16.6M backed by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2019): $10M with participation from Roth Capital Partners
Debt (2020): $150K led by PPP
Share Placement (2023): $102.9M supported by Rosalind Advisors and Second Line
Stock/Share Issuance (2025): $2.5M, investors not publicly disclosed
Key Investors in Cellectar Biosciences
Rosalind Advisors
Rosalind Advisors, Inc. specializes in life science investing and manages biotech funds. The company focuses on providing investment opportunities in the life sciences sector.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
Roth Capital Partners
Roth MKM is a privately-owned investment banking firm with a premier suite of business lines ranging from M&A, financing, restructuring, advisory, and corporate services. They strive to produce innovative, actionable, and proprietary content for their clients.
What's next for Cellectar Biosciences?
With the recent injection of major strategic capital, Cellectar Biosciences is poised for significant advancements. The company's trajectory suggests a focus on scaling its clinical trial operations and potentially preparing for later-stage development or commercialization activities. The enterprise-level funding context indicates a company moving beyond early-stage research and development towards solidifying its market position. Future strategic moves may involve expanding its pipeline, forging key partnerships, or advancing its lead candidate through regulatory pathways. The company's commitment to addressing unmet needs in oncology positions it for continued growth and impact in the biopharmaceutical landscape.
See full Cellectar Biosciences company page
